https://www.ampulmonary.com/asthma/article/22976064/common-asthma-gene-variant-may-influence-response-to-biologic-therapyPulmonaryen2026-10-08T19:03:46.000ZCommon asthma gene variant may influence response to biologic therapyhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/gettyimages-858855602.cLJRQBJgBi.jpg?auto=format%252Ccompress&q=70https://www.ampulmonary.com/asthma/article/22976061/ai-falls-short-of-human-experts-in-assessing-severe-asthma-treatment-decisionsPulmonaryen2026-10-08T18:54:06.000ZAI falls short of human experts in assessing severe asthma treatment decisionshttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/gettyimages-2244095178.gQNcsOPduf.jpg?auto=format%252Ccompress&q=70https://www.ampulmonary.com/copd/article/22976024/regular-walking-helps-patients-with-copd-in-areas-of-high-air-pollutionPulmonaryen2026-10-08T15:31:43.000ZRegular walking helps patients with COPD in areas of high air pollutionhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/walking-air-pollution.A8kLXbleE2.jpg?auto=format%252Ccompress&q=70https://www.ampulmonary.com/copd/article/22976023/novel-copd-treatment-shows-positive-preliminary-results-in-phase-2-trialPulmonaryen2026-10-08T15:28:11.000ZNovel COPD treatment shows positive preliminary results in phase 2 trialhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/rademikibart.WtSGdEbBUl.jpg?auto=format%252Ccompress&q=70https://www.ampulmonary.com/pulmonary/article/22975960/novel-ai-model-predicts-pneumonitisPulmonaryen2026-10-07T18:15:27.000ZNovel AI model predicts pneumonitishttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/cipher-md-anderson.Vq3F4I2Xxj.jpg?auto=format%252Ccompress&q=70CIPHER, an AI-powered CT foundation model, identifies patients with lung cancer at increased risk of immunotherapy-induced pneumonitis before treatment begins. The AI-generated output, shown here, highlights lung abnormalities to support early risk assessment and personalized patient care.https://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/jiu-wu-phd-md-anderson.ziNtvLb6xV.jpg?auto=format%252Ccompress&q=70Jia Wu, PhDhttps://www.ampulmonary.com/pulmonary/article/22976051/sex-differences-in-metabolism-impact-lung-tumor-growthPulmonaryen2026-10-06T17:58:00.000ZSex differences in metabolism impact lung tumor growthhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/gettyimages-2243181755.glebBkGvoh.jpg?auto=format%252Ccompress&q=70https://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/uclapress-ca-akg.w5zvlID8KN.jpg?auto=format%252Ccompress&q=70A figure showing lung sections from male and female mice in the two groups. The tumors are highlighted by the red areas.https://www.ampulmonary.com/pulmonary/article/22975651/cf-triple-therapy-the-earlier-the-betterPulmonaryen2026-10-02T16:45:04.000ZCF triple therapy: The earlier, the betterhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/charite-cystic-fibrosis-triple-therapy.IDr5s7Wd3R.png?auto=format%252Ccompress&q=70The intestinal mucosa with its characteristic invaginations, the intestinal crypts (blue). At the lower end of the crypts are the CFTR channels, whose function is impaired in cystic fibrosis.https://www.ampulmonary.com/home/article/22975610/mast-cells-emerge-as-central-drivers-of-allergic-asthmaPulmonaryen2026-10-02T01:08:53.000ZMast cells emerge as central drivers of allergic asthmahttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/gettyimages-1488349703.5zKgMOBArH.jpg?auto=format%252Ccompress&q=70https://www.ampulmonary.com/asthma/article/22975608/achieving-asthma-remission-with-triple-therapyPulmonaryen2026-10-02T00:59:34.000ZTriple versus dual inhaler therapy for asthma controlhttps://img.ampulmonary.com/mindful/ascend/workspaces/default/uploads/2026/10/gettyimages-1700712757.4oXRABpxHU.jpg?auto=format%252Ccompress&q=70